NURS6501 is the first population-focused course in the PMHNP specialization, building on the foundational assessment and diagnostic skills from the MSN core to develop advanced competency in managing psychiatric conditions specific to adult and geriatric populations. Students learn to assess, diagnose using DSM-5-TR criteria, develop treatment plans integrating pharmacotherapy and psychotherapy, and manage the unique complexities that arise when psychiatric illness intersects with aging, medical comorbidity, and cognitive decline.
Psychiatric conditions in adults and older adults
| Diagnostic Category | Adult Presentation | Geriatric-Specific Considerations |
|---|---|---|
| Major depressive disorder | Persistent sad mood, anhedonia, sleep/appetite changes, concentration difficulty, suicidal ideation | Often presents as somatic complaints, cognitive impairment (pseudodementia), social withdrawal, or failure to thrive rather than expressed sadness |
| Generalized anxiety disorder | Excessive worry, restlessness, muscle tension, sleep disturbance, concentration difficulty | May present as physical complaints, excessive medical help-seeking, or worries focused on health and mortality |
| Schizophrenia spectrum | Positive symptoms (hallucinations, delusions), negative symptoms, cognitive deficits, functional impairment | Late-onset schizophrenia (>40) more common in women; visual hallucinations raise concern for Lewy body dementia |
| Bipolar disorders | Manic/hypomanic episodes alternating with depression, mood cycling, impulsivity, psychosis in severe mania | Late-onset mania often secondary to medical conditions (stroke, tumor, medication-induced); lithium requires renal monitoring and lower doses in elderly |
| Substance use disorders | Alcohol, opioids, benzodiazepines, stimulants; tolerance, withdrawal, functional impairment | Alcohol misuse underrecognized in elderly; benzodiazepine dependence from long-term prescribing; lower thresholds for intoxication |
| Neurocognitive disorders | Not typically diagnosed in younger adults unless secondary to TBI/substance use | Alzheimer disease, vascular dementia, Lewy body dementia, frontotemporal dementia — differential diagnosis and behavioral management central to geriatric psych |
What NURS6501 covers
Adult psychopharmacology is a core focus of NURS6501. Students learn evidence-based medication selection for major depressive disorder (first-line SSRIs, switching strategies, augmentation with atypical antipsychotics or lithium for treatment-resistant depression), anxiety disorders (SSRIs/SNRIs as first-line, buspirone, appropriate and inappropriate benzodiazepine use), psychotic disorders (first- and second-generation antipsychotics, metabolic monitoring, clozapine for treatment-resistant schizophrenia), and bipolar disorder (lithium, valproate, lamotrigine, atypical antipsychotic mood stabilizers). For each medication class, students learn mechanism of action, dosing, monitoring parameters, drug interactions, and side effect management.
Geriatric psychopharmacology receives special emphasis because aging fundamentally alters drug metabolism. Decreased hepatic blood flow and reduced CYP450 enzyme activity slow drug metabolism; decreased renal function impairs drug clearance; increased body fat increases the volume of distribution for lipophilic drugs (extending half-lives); decreased albumin increases free drug levels. The clinical implication: "start low, go slow, but go" — lower starting doses, slower titration, but still reaching therapeutic levels. NURS6501 covers geriatric-specific prescribing for every major medication class, including the Beers Criteria for potentially inappropriate medications in older adults.
Working on an adult psychiatric case study, geriatric psychopharmacology paper, or neurocognitive disorder analysis?
Our PMHNP writers develop adult and geriatric psychiatric papers with the clinical depth Capella's NURS6501 rubric requires.
Key topics in NURS6501
- Adult mood disorders: MDD assessment, DSM-5-TR criteria, psychopharmacology algorithms, suicide risk assessment
- Anxiety disorders: GAD, panic disorder, social anxiety, OCD — diagnosis and evidence-based treatment
- Psychotic disorders: schizophrenia, schizoaffective disorder, brief psychotic disorder — antipsychotic management
- Bipolar disorders: mania assessment, mood stabilizer selection, monitoring, pregnancy considerations
- Substance use disorders: screening (AUDIT, DAST), motivational interviewing, medication-assisted treatment
- Neurocognitive disorders: Alzheimer's, Lewy body, vascular, frontotemporal — differential and behavioral management
- Geriatric psychopharmacology: age-related pharmacokinetic changes, Beers Criteria, polypharmacy, deprescribing
- Psychotherapy integration: CBT, supportive therapy, motivational interviewing with pharmacotherapy
Distinguishing dementia from depression in older adults (pseudodementia)
- Onset: depression — relatively rapid (weeks); dementia — insidious (months to years)
- Awareness: depressed patients emphasize cognitive complaints; dementia patients minimize or are unaware of deficits
- Effort: depressed patients often respond "I don't know" on cognitive testing (low effort); dementia patients try but give incorrect answers
- Mood: depression — persistent sadness or emptiness; dementia — mood may be normal until later stages (apathy more than sadness)
- Reversibility: pseudodementia improves with antidepressant treatment; true dementia does not (but depression and dementia frequently co-occur)
- Key clinical point: treat the depression first — if cognition improves, the primary diagnosis was depression with cognitive features; if cognition does not improve, pursue dementia workup
Get Help With NURS6501
Adult psychiatric case studies, geriatric psychopharmacology papers, neurocognitive disorder analyses. PMHNP coursework done right.
Place Your OrderView All ServicesRelated courses
Frequently asked questions
Older adults with depression frequently present with somatic complaints (fatigue, pain, GI distress, insomnia), cognitive impairment, social withdrawal, or functional decline rather than the "textbook" sadness and tearfulness. Several factors explain this: generational attitudes that stigmatize mental illness and frame emotional complaints as weakness; alexithymia (difficulty identifying and expressing emotions) which increases with age; the overlap between depression symptoms and symptoms of chronic medical conditions; and neurobiological changes associated with late-life depression that preferentially affect executive function and processing speed rather than mood regulation alone. The PMHNP must screen proactively using validated tools (PHQ-9, GDS) rather than relying on patient-reported sadness.
Alzheimer disease (AD) is the most common dementia, characterized by insidious onset of memory impairment (especially short-term memory) followed by progressive decline in language, visuospatial function, and executive function. Lewy body dementia (DLB) is characterized by a triad of fluctuating cognition, visual hallucinations (often detailed, well-formed images), and parkinsonism (rigidity, bradykinesia, shuffling gait). The psychiatric significance: DLB patients are exquisitely sensitive to antipsychotics — even low doses can cause severe neuroleptic malignant syndrome-like reactions, worsened parkinsonism, or death. This makes correct differential diagnosis critical before prescribing any antipsychotic for behavioral management in dementia.
MAT combines FDA-approved medications with counseling and behavioral therapies. For opioid use disorder: buprenorphine (Suboxone), methadone, or naltrexone (Vivitrol). For alcohol use disorder: naltrexone, acamprosate, or disulfiram. For tobacco: nicotine replacement, varenicline (Chantix), or bupropion. PMHNPs with DEA X-waiver (now universal under the MAT Act of 2023 — all DEA-registered practitioners can prescribe buprenorphine without additional waiver) can prescribe buprenorphine for opioid use disorder. NURS6501 covers MAT because substance use disorders are psychiatric conditions, not moral failings, and the PMHNP must be competent in evidence-based pharmacotherapy for addiction alongside traditional psychiatric conditions.
Aging changes pharmacokinetics in ways that increase drug exposure at standard adult doses: hepatic metabolism slows (reduced CYP450 activity), renal clearance decreases (even without diagnosed CKD), body composition shifts increase fat-soluble drug half-lives, and decreased albumin increases free drug levels. Additionally, older adults have increased CNS sensitivity to psychotropics — they experience more sedation, cognitive impairment, orthostatic hypotension, and anticholinergic effects at lower blood levels. Starting at 25–50% of the standard adult dose and titrating slowly reduces adverse effects while still reaching therapeutic efficacy. "But go" is equally important: under-dosing due to age-related caution leaves treatable psychiatric illness untreated.